IgM paraproteins in about 50% of the patients with neuropathy associated with IgM gammopathy react with carbohydrate moieties in myelinassociated glycoprotein (MAG) and in sulfated glucuronic glycolipids (SGGLs) in human peripheral nerves. However, the role of anti-MAG/SGGL antibodies in the pathogenesis of neuropathy remains unclear. In order to induce an animal model of neuropathy associated with anti-MAG/SGGL antibodies, cats were immunized with sulfoglucuronyl paragloboside (SGPG). All four cats immunized with SGPG developed clinical signs of sensory neuronopathy within 11 months after initial immunization, characterized by unsteadiness, falling, hind limb weakness and ataxia. In two cats the ataxia and hind limb paralysis were so severe that the animals had to be euthanized. Pathological examination revealed sensory ganglionitis with inflammatory infiltrates in the dorsal root ganglia. No overt signs of pathology were noted in the examined roots or nerves. High titer anti-SGPG/MAG antibodies were detected in all 4 cats immunized with SGPG but not in 3 control cats. Our data demonstrate that immunization of cats with SGPG induced anti-SGPG antibodies and sensory neuronopathy clinically resembling the sensory ataxia of patients with monoclonal IgM anti-MAG/SGPG antibodies. This study suggests that these anti-MAG/SGPG antibodies play a role in the pathogenesis of this neuropathy.
Introduction
Paraproteinemic neuropathies are a diverse group of disorders in which there is an excessive amount of monoclonal antibody termed a paraprotein, and are also called monoclonal gammopathies. IgM is the most common paraprotein in patients with neuropathy and in more than seventy percent of these patients IgM paraproteins react with oligosaccharide moieties of glycoproteins and glycolipids (Latov 1995; Quarles and Weiss, 1999, Quarles 2007; Willison and Yuki, 2002; Nobile-Orazio, 2004; Ilyas, in press ). IgM paraproteins in about 50% of the patients with neuropathy associated with IgM gammopathy react with carbohydrate moieties in several myelin glycoproteins including myelin-associated glycoprotein (MAG), P0 glycoprotein and peripheral myelin protein-22 (PMP-22) and also in sulfated glucuronic glycolipids (SGGLs) in human peripheral nerves (Ilyas et al., 1984, Ilyas, in press; Latov 1995; Quarles and Weiss, 1999, Quarles, 2007; Willison and Yuki, 2002; Nobile-Orazio, 2004 ). These glycoconjugates also react with a mouse monoclonal antibody HNK-1 (Leu-7) directed against human natural killer cells (Chou et al., 1986; McGarry et al., 1983) . Two SGGLs from human peripheral nerves have been characterized. They are sulfated glucuronyl paragloboside (SGPG) and sulfated glucuronyl lactosaminyl paragloboside (SGLPG) (Chou et al., 1986; Ariga et al., 1987) . The terminal sulfated glucuronic acid in SGPG is a critical part of the epitope for all anti-MAG/SGPG IgM paraproteins and for monoclonal HNK-1 antibody (Ilyas et al., 1986 (Ilyas et al., , 1990 (Ilyas et al., , 1992 .
Most patients with anti-MAG/SGPG IgM paraproteins have a chronic, slowly progressive, predominantly sensory, ataxic, demyelinating neuropathy (Nobile-Orazio et al., 1994; Van den Berg et al., 1996; Chassande et al., 1998 
